However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...

The IPO, which saw 25 million shares sold at $16, in the middle of the $15 to 17 range predicted by the company, continues a ...

As Rare Disease Day approaches, the lessons from recent European launches are clear: success comes from disciplined operating models, disease‑centred engagement, pragmatic evidence strategies, and ...

Oxford-based Sitryx, which also has operations in Boston in the US, was founded in 2018 with seed funding from SV Health ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Asahi Kasei has agreed a €780 million (around $920 million) price tag for Wuppertal-based Aicuris, which is hoping for FDA ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News headlines, on your Instagram feed, song lyrics, in day-to-day conversation; few ...

As Rare Disease Day approaches, in a special episode of the pharmaphorum podcast, sponsored by AOP Health, we spoke with Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, at AOP ...

Faruk Capan: AI is incredibly powerful at designing a smarter “front door.” In the GLP-1 space, this could mean the technology could quickly capture medical history, check for comorbidities, analyse ...

Retention has always been a central concern in long-term studies, but obesity trials present a particular challenge. For those assigned to receive the drug candidate in question, the effects are ...